EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Botulinum toxin type B in piriformis syndrome



Botulinum toxin type B in piriformis syndrome



American Journal of Physical Medicine & Rehabilitation 83(3): 198-202



To evaluate the clinical safety and efficacy of botulinum toxin type B (MYOBLOC) in reducing myofascial pain associated with piriformis syndrome. This was a single-center, outpatient, open-label study of patients with piriformis syndrome. Subjects were treated unilaterally or bilaterally, depending on their symptoms. Evaluations and procedures were performed by a single examiner who was not blinded, and there were no control subjects in this case series. Each piriformis muscle was infiltrated from one injection site under electromyographic guidance with 5000 units of botulinum toxin type B. A total of 20 patients were enrolled in this study. Significant reductions in mean visual analog scale scores for buttock and hip pain were noted at weeks 4, 12, and 16 and for low back pain at weeks 2, 12, and 16. Visual analog scale scores for general and low back pain, pain radiating into lower limbs, and tingling were significantly lower at week 2 after injection, suggesting early onset. A total of 95% of patients reported fair to excellent improvement in pain. Botulinum toxin type B was considered to have fair to excellent efficacy in 90% of patients, as evaluated by the investigator rating of overall efficacy. Botulinum toxin treatment was well tolerated. Dry mouth was the most common treatment emergent adverse event, reported in 6 of 20 patients. Findings suggest the possibility that botulinum toxin type B may be of potential benefit in the treatment of pain attributed to piriformis syndrome.

(PDF emailed within 0-6 h: $19.90)

Accession: 048403792

Download citation: RISBibTeXText

PMID: 15043354

DOI: 10.1097/01.phm.0000113404.35647.d8



Related references

An MRI evaluation of changes in piriformis muscle morphology induced by botulinum toxin injections in the treatment of piriformis syndrome. Diagnostic and Interventional Imaging 96(1): 37-43, 2015

Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. American Journal of Physical Medicine & Rehabilitation 81(10): 751-759, 2002

Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome. PharmacoTherapy 27(5): 657-665, 2007

Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins 7(8): 3045-3056, 2016

Usefulness of Magnetic Resonance Neurography for Diagnosis of Piriformis Muscle Syndrome and Verification of the Effect After Botulinum Toxin Type A Injection: Two Cases. Medicine 94(38): E1504-E1504, 2015

Treatment of piriformis syndrome with botulinum toxin. Jost, W H , Reprint Author Botulinum toxin in painful diseases: 140-158, 2003

Treatment of Piriformis Muscle Syndrome with Botulinum Toxin-A. Anesthesiology Abstracts of Scientific Papers Annual Meeting ( ): Abstract No A-879, 2002

Botulinum toxin in the treatment of piriformis syndrome The predictive value of d-tubocurare. Regional Anesthesia & Pain Medicine 26(2 Supplement): 102, March-April, 2001

Piriformis muscle syndrome (PMS): Review of diagnostic criteria and therapeutic proposals, including the effect of botulinum toxin, in a series of 32 cases. 2007

Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study. American Journal of Physical Medicine & Rehabilitation 83(1): 42-50; Quiz 51-3, 2004

The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatologic Surgery 39(3 Pt 2): 510-525, 2013

Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX (R)) in healthy volunteers. Journal of Neural Transmission 112(7): 905-913, 2005

BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Movement Disorders 12(5): 772-775, 1997

Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. Journal of Neural Transmission 112(7): 905-913, 2004

Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatologic Surgery 29(5): 519-22; Discussion 522, 2003